Influence of temperature, needle gauge and injection rate on the size distribution, concentration and acoustic responses of ultrasound contrast agents at high frequency by Sun, Chao et al.
Accepted Manuscript
Influence of temperature, needle gauge and injection rate on the size distribution,
concentration and acoustic responses of ultrasound contrast agents at high fre-
quency
Chao Sun, Ioanna Panagakou, Vassilis Sboros, Mairead B. Butler, David
Kenwright, Adrian J.W. Thomson, Carmel M. Moran
PII: S0041-624X(16)30024-5
DOI: http://dx.doi.org/10.1016/j.ultras.2016.04.013
Reference: ULTRAS 5262
To appear in: Ultrasonics
Received Date: 18 September 2015
Revised Date: 16 February 2016
Accepted Date: 16 April 2016
Please cite this article as: C. Sun, I. Panagakou, V. Sboros, M.B. Butler, D. Kenwright, A.J.W. Thomson, C.M.
Moran, Influence of temperature, needle gauge and injection rate on the size distribution, concentration and acoustic
responses of ultrasound contrast agents at high frequency, Ultrasonics (2016), doi: http://dx.doi.org/10.1016/j.ultras.
2016.04.013
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
 1
                                                                                                                                                                   
Influence of temperature, needle gauge and injection rate on the size 
distribution, concentration and acoustic responses of ultrasound 
contrast agents at high frequency  
Chao Sun, *$ Ioanna Panagakou, * Vassilis Sboros, *† Mairead B Butler, *† David 
Kenwright, * Adrian JW Thomson, * Carmel M Moran * 
 
*Medical Physics, Centre for Cardiovascular Research, University of Edinburgh, 
Edinburgh, UK; $Ultrasound Department, Xijing Hospital, Xi’an, China; †Institute of 
Biochemistry, Biophysics and Bioengineering, Heriot-Watt University, Edinburgh, 
UK 
 
Corresponding author: Carmel M Moran 
Email: carmel.moran@ed.ac.uk 
Postal address:  
Room E3.06, Centre for Cardiovascular Science, Queen's Medical Research Institute 
The University of Edinburgh 
47 Little France Crescent 
Edinburgh, UK  
EH16 4TJ 
  
 2
ABSTRACT  
This paper investigated the influence of needle gauge (19G and 27G), injection rate 
(0.85ml·min-1, 3ml·min-1) and temperature (room temperature (RT) and body 
temperature (BT)) on the mean diameter, concentration, acoustic attenuation, contrast 
to tissue ratio (CTR) and normalised subharmonic intensity (NSI) of three ultrasound 
contrast agents (UCAs): Definity, SonoVue and MicroMarker (untargeted). A 
broadband substitution technique was used to acquire the acoustic properties over the 
frequency range 17–31 MHz with a preclinical ultrasound scanner Vevo770 
(Visualsonics, Canada). Significant differences (P<0.001 - P<0.05) between typical in 
vitro setting (19G needle, 3ml·min-1 at RT) and typical in vivo setting (27G needle, 
0.85ml·min-1 at BT) were found for SonoVue and MicroMarker. Moreover we found 
that the mean volume-based diameter and concentration of both SonoVue and 
Definity reduced significantly when changing from typical in vitro to in vivo 
experimental set-ups, while those for MicroMarker did not significantly change. From 
our limited measurements of Definity, we found no significant change in attenuation, 
CTR and NSI with needle gauge.  For SonoVue, all the measured acoustic properties 
(attenuation, CTR and NSI) reduced significantly when changing from typical in vitro 
to in vivo experimental conditions, while for MicroMarker, only the NSI reduced, 
with attenuation and CTR increasing significantly. These differences suggest that 
changes in physical compression and temperature are likely to alter the shell structure 
of the UCAs resulting in measureable and significant changes in the physical and high 
frequency acoustical properties of the contrast agents under typical in vitro and 
preclinical in vivo experimental conditions. 
KEY WORDS: High frequency ultrasound, microbubble, needle gauge, injection rate, 
temperature, acoustic characterisation 
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 1 INTRODUCTION 
There is an increasing number of applications for the use of UCAs in the preclinical 
field [1], with an associated increase in the number of published studies utilising 
UCAs both in vivo and in vitro [2-5].  However, the differences between the 
administration of UCAs in an in vivo environment at body temperature and an in vitro 
experiment at room temperature need to be considered.  The size of needle gauges 
used for small animal in vivo injections are often not cited in the literature but 
generally range from 24G for rat tail vein injection [6] , 27G for mouse tail vein 
injection [7] and in larger animals - 30G for pig cervical region of nerve [8] and dog 
lymphatic system [9]. Generally in vitro experiments of UCAs are performed at room 
temperature using 18G - 20G needle gauges – sizes which are widely used in clinical 
practice and specifically recommended by some contrast agent manufacturers [10]. 
When bolus injections are undertaken in small animals, although the bolus is 
considerably smaller (of the order of microliters), it is generally performed at an 
injection rate of between 0.5 - 3 ml/min, a rate that is commonly used for clinical 
bolus intravenous injections.  
 
1.1 The influence of temperature  
The three commercial UCAs: Definity (Lantheus Medical Imaging, USA), SonoVue 
(Bracco, Italy) and MicroMarker (untargeted) (Visualsonics, Canada) are lipid-coated 
microbubbles (MBs). The shells of the three UCAs are monolayers but each is formed 
from a varying combination of different lipids.  As a result, it is difficult to determine 
a specific phase transition temperature for the lipid shells of each and hence the effect 
of temperature on the lipid-coated MBs is unknown and its resultant influence on 
microbubble characteristics is unclear. The fluid-gel phase transition temperature of 
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lipids in bilayer states varies from -1°C to 75°C [11] and -1°C to 55°C [12] depending 
on the phospholipids acyl chain length. Lipid molecules are limited on the membrane 
plane in two phases – either fluid: liquid phase; or gel: solid phase, where the liquid 
phase allows a freer diffusion of molecules than in the solid phase [13]. For this 
reason, the viscosity, elasticity, free energy and diffusion coefficient of the MB lipid 
shell can be changed below, at, or above the transition temperature [12]. The lipid 
shell of Definity consists of three phospholipids (DPPA, DPPC and MPEG 5000 
DPPE) [3]. The lipids incorporated into MicroMarker shell are polyethylene glycol, 
phospholipids (unspecified) and fatty acids (VisualSonics PN11691) [14]. SonoVue 
possesses an amphiphilic phospholipid shell  (a hydrophilic surface outside and a 
hydrophobic surface inside) [15] and involves two lipids (DSPC and DPPG) [16].  
 
The thermal response of SonoVue has previously been studied over the temperature 
range 37-43oC and its lipid transition temperature was inferred to be 40oC, from 
observation of changes in its maximal diameter and backscatter intensity (ultrasound 
frequency: 2.5- 8MHz, low MI: 0.0081- 0.113) [17].  For Definity and MicroMarker, 
the attenuation was measured and found to be higher at 37°C than at 25°C over a 
frequency range from 2 to 25MHz.  Measurements were undertaken in bovine serum 
albumin and whole blood and no difference in attenuation was found between the two 
diluents [14].  Individual Definity and SonoVue MBs have previously been measured 
at room temperature (21oC) and body temperature (37oC) using a high speed optical 
camera under an insonation of 1.7MHz, 10-80kPa pulse [18]. Compared with the 
performance at room temperature, Definity and SonoVue showed an increase in radial 
expansion and a decrease in onset of acoustic oscillation at body temperature.  
Extensive temperature dependence studies of SonoVue were completed using 3.5 
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MHz-ultrasound [16, 19]. Increasing the temperature close to the transition 
temperature resulted in bubbles exhibiting greater radial expansion. Expanding MBs 
and rapid diffusion was shown to increase the mean diameter, attenuation, backscatter 
and nonlinear components.  
 
1.2 The effect of needle size and injection rate  
Talu [20] measured the variation in concentration and mean diameter of one in-house, 
lipid-encapsulated UCA at 3 concentrations (1, 5, 10×108 MBs·ml-1) using 3 needle 
gauges (23G, 27G and 30G) at 5 injection rates (0.01, 0.03, 0.1, 0.3 and 0.5 ml.sec-1). 
With increasing needle gauge (decreasing inner needle diameter), the measured 
concentration of microbubbles was shown to decrease suggesting destruction of the 
MBs. In addition, a reduction in mean diameter was observed and attributed to an 
overall decrease in number of MBs in the population. It was suggested that this was 
due to diffusion by the forced compression and possible preferential destruction of 
large MBs. A similar study investigating the influence of administration variables (2 
needle gauges: 18G and 25G; 2 syringes: 5ml and 10ml; 5 discrete flow rates from 2 
to 3.3 ml·min-1; 2 suspending fluids: distilled water and 95% volume-glycerol) was 
performed using another in-house lipid MB [21].  The results from this study showed 
that in addition to the hydrostatic pressure, shear stress due to the increasing pressure 
and velocity gradient played a key role in destroying MBs. However, this study found 
that an increasing volume flow rate (i.e., injection rate) reduced the destruction of 
MBs, which is not in agreement with the study of Talu [20]. The discrepancy was 
attributed to the difference in initial diameter, size distribution, concentration and 
composition of MBs.  An in vivo experiment to improve plasmid transfection using 
SonoVue MBs-mediated gene transfection tested the effects of using 3 needle gauges 
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(25G, 27G and 29G) and showed that increasing needle gauge increased MB 
destruction and reduced MB diameter [22].  
 
From the above studies, temperature, needle gauge and injection rate have been 
shown to have significant effects on the size distribution and acoustic properties of 
UCAs. However, the implications of these results for preclinical studies remain 
unclear. This is due to several factors. Firstly, the previous studies are limited to the 
ultrasound frequencies relevant for clinical applications and little research has been 
performed at high frequencies applicable for preclinical applications. Secondly, the 
effect of temperature, needle gauge and injection rate have been discussed separately 
but the potential interactions between them remain indistinct. Thirdly, a wide range of 
in-house MBs have been studied while commercial UCAs (both clinical and 
preclinical) are the products that are most commonly used for preclinical studies and 
the influence of these parameters on these commercial agents has not been fully 
investigated at high frequencies. 
 
The aim of this paper is to investigate the influence of needle gauge, injection rate and 
temperature on the mean diameter, concentration, acoustic attenuation, contrast to 
tissue ratio (CTR) and normalised subharmonic intensity (NSI) of solutions of 
Definity, SonoVue and MicroMarker (untargeted) over the frequency range of 17-
31MHz.  In particular, the changes observed in these measurements for SonoVue and 
MicroMarker, the most commonly used contrast agents for preclinical studies, under 
typical in vivo and in vitro experimental conditions will be discussed.  
 
2 METHOD AND MATERIALS 
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2.1 UCAs preparation  
UCAs were reconstituted based on the manufacturers’ guidelines and were ready for 
experimental use after standing at room temperature for 20 minutes.  The information 
of the three UCAs is listed in Table 1. Based on the maximum concentration from the 
manufacturer’s published literature, MBs were diluted in air saturated distilled water 
to reach a concentration of 0.8×106 MBs·ml-1.  At this concentration, the occurrence 
of multiple scattering and shadowing of Definity MBs was previously shown to be 
avoided [23]. 
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Table 1: The parameters and dilution of contrast agents, *Definity [10], SonoVue [24, 25], ‡MicroMarker [26] 
 
 
 
 
 
 
 
 
 
Name Gas Shell Number-
based mean 
diameter 
(µm)    
Maximum 
concentration after 
reconstitution 
(mbs/ ml) 
Dilution 
in this 
study 
Manufacturer 
*
 Definity® C3F8 Phospholipids 1.1-3.3  1.2×1010 1:15000 Lantheus Medical 
Imaging, USA 
†SonoVue® SF6 Phospholipids 2-3 5×108  1:625 Bracco, Italy 
‡MicroMarkerTM 
untargeted contrast 
agent 
C4F10 / 
N2 
Polyethylene glycol, 
Phospholipids and fatty 
acid 
2.3-2.9  2×109  
 
1:2500 Visualsonics, Canada
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2.2 The control of needle gauge and injection rate 
In this study, two needles (19G and 27G) (Becton, Dickinson and Company (BD), 
USA) are selected: a 19G (internal diameter (ID) = 0.686mm) needle is generally used 
in human intravenous injection and also in some in vitro experiments while a 27G (ID 
= 0.21mm) needle is commonly used for mouse-tail injections and mouse intra-
cardiac injections. Two injection rates are studied: 0.85 ml·min-1 and 3ml·min-1, where 
0.85 ml·min-1 is a typical injection rate used in bolus injections into a mouse tail vein 
during preclinical studies and 3 ml·min-1 a typical injection rate applied in in vitro 
experiments. The steady and reproducible injection rate was controlled using a 
syringe pump (Aladdin, World Precision Instruments Inc., USA) by connecting the 
test needle with 1ml-syringe (ID = 4.78 mm) to reach an injection rate of 0.85 ml⋅min-
1
 and 2ml-syringe (ID=8.66 mm) to reach a 3ml·min-1injection rate. 
 
2.3 Temperature control and the measurement of dissolved oxygen level 
The entire experiment was undertaken in air saturated distilled water (diluent) at both 
room temperature (RT: 20 2oC) and body temperature (BT: 37 2oC). Two-degree 
Celsius is the maximal range of variation in temperature. The water was determined to 
be air-saturated using the dissolved oxygen content in the water. This was monitored 
using a dissolved oxygen probe (Vernier Software & Technology, OR, USA) using 
the assumption that oxygen (O2) and nitrogen (N2) are the dominant gases in the water 
and that the dissolved O2 is proportional to the N2 at atmospheric pressure under 
Henry’s law [27]. The air-saturated water at RT was prepared by leaving the distilled 
water over 24 hours. The air-saturated water at BT was obtained by heating the water 
to 42oC then degassing using a vacuum pump. The resultant air saturated water at BT 
± ±
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was sealed in a bottle and placed on a hotplate, to maintain the temperature of the 
water throughout the experiment. 
 
For the process of withdrawing Definity and MicroMarker, a 19G needle was inserted 
into the vial of activated contrast agent, a second 19G was inserted for venting the gas 
as per the manufacturer’s recommendations. One of the 19G needles was connected to 
a syringe and the Definity or MicroMarker was withdrawn at a steady slow rate of 
approximately 1.5ml⋅min-1. For SonoVue, once it was formulated it was withdrawn 
from its vial using a needleless syringe provided by the manufacturer at a speed 
similar to that used to withdraw Definity and MicroMarker.  The choice of syringe 
selected for the experiments depended on the injection rate selected (1ml-syringe for 
0.85 ml·min-1 and 2ml-syringe for 3ml·min-1). The syringe was then placed 
horizontally on a syringe pump and connected with one of the needles under test. At 
the injection rate setting, UCAs were collected from the needle tip into an Eppendorf 
PCR tube and were then diluted ready for sizing and acoustical measurement. The 
experiments undertaken at BT were performed in an identical manner except that the 
diluent was the prepared air-saturated water at BT. Because the MBs suspension was 
placed in an open tank and stirred continuously throughout the acoustic measurements, 
the water tank was placed on a hotplate to maintain the temperature at BT.  
 
Details of the different combinations of needle gauge, injection rate and temperature 
for each experiment are shown in Table 2. In this study, the choice of a 19G needle, 
an injection rate of 3ml·min-1 in a diluent at RT is defined as ‘in vitro’ representing a 
typical in vitro situation. The choice of a 27G needle, an injection rate of 0.85ml·min-1 
in a diluent at BT is defined as an ‘in vivo’ experimental setting. For analysis of the 
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data, the ‘in vitro’ setting was defined as the control group and all data was compared 
to this. Consequently for each agent, comparison between the 19G and 27G 
experimental data at the same injection rate (3ml·min-1) and temperature (RT) reveals 
impact of the needle gauge.  Comparison between the 3ml·min-1 and 0.85ml·min-1 at 
the same needle gauge (19G) and temperature (RT) enables the impact of the injection 
rate to be determined, and between the RT and BT at the same needle (19G) and 
injection rate (3ml·min-1) the impact of temperature can be determined for 
MicroMarker and SonoVue. Finally between the in vitro and in vivo settings the 
combined impact of temperature, injection rate and needle gauge size can be 
determined. For Definity and SonoVue, the mean diameter was acquired for all 
experimental settings, however for MicroMarker only the data from the in vitro and in 
vivo were acquired. The acoustical properties of Definity at 370C are not included in 
this study. 
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Table 2. The specific experimental settings for the five groups 
 
 
2.4 Characterisation of diameter and concentration 
The mean diameter of the three UCAs was measured by a laser diffraction particle 
analyser Mastersizer 2000 Hydro MU (Malvern Instruments Ltd, Malvern, UK). 
Three measurements were taken from each sample and the mean values displayed. 
The variation in concentration was measured using haemocytometers (FastRead 102 
Counting Slides, Immune Systems Ltd, UK) and an inverted microscope (Zeiss 
Axiovert 25) under a 40× magnification. MBs were manually counted in a 4×4-
counting grid for each experimental set-up. Each experimental setting was repeated 
three times for each agent yielding a mean value of 9 counts for each agent at each 
experimental setting. 
 
2.5 Acoustic characterisation 
A Vevo 770 preclinical ultrasound scanner (VisualSonics Inc., Canada) was used to 
measure the acoustic properties of the contrast agents. Details of the measurement 
technique can be found in [28, 29] and only a brief summary will be described here. 
The transducer was placed perpendicular to a polymethylpentene (TPX) reflector 
Group name In vitro Needle Gauge Injection 
Rate 
Temperature In vivo 
Needle gauge 19G 27G 19G 19G 27G 
Injection rate 
(ml·min-1) 
3 3 0.85 3 0.85 
Temperature RT RT RT BT BT 
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(Boedeker Plastics, Shiner, TX, USA) in a water tank (length: width: height = 4cm: 1 
3cm: 5cm) on a magnetic stirrer (RCT basic, IKA, US).  A magnetic bar (3mm-OD, 2 
1cm-length) was placed in the tank to ensure a homogeneous MB suspension. One 3 
transducer 707B with nominal centre frequency of 30MHz, a focal length of 12.7mm, 4 
a 3dB bandwidth ranging from 17-31MHz, a 6dB bandwidth of 13-35MHz at 3% 5 
transmitting power (the peak negative pressure (PNP) was measured to be -0.56 MPa) 6 
performed as both a transmitter and receiver. The PNP was confirmed using a 7 
membrane hydrophone with a 0.2mm diameter active element made of Polyvinylidene 8 
Fluoride (PVDF) (Precision Acoustics Ltd., Dorchester, UK). The PNP of -0.56 MPa 9 
was chosen as we have previously demonstrated that microbubbles were not disrupted 10 
at this PNP and frequency at RT [29]. 11 
 12 
2.6 Data analysis 13 
The attenuation and contrast to tissue ratio (CTR) of the MB suspension were 14 
measured in this study to evaluate the fundamental acoustic signature of UCAs. The 15 
measurements of attenuation coefficient, α, and CTR as a function of frequency are 16 
described in more detail in Sun et al. [29].  In this study, both the attenuation and CTR 17 
were averaged over the 3dB bandwidth of the transducer giving a mean value. 18 
 19 
The normalised subharmonic intensity (NSI) of backscatter is measured to 20 
characterise the nonlinear property of the UCAs using Equation 1.  21 
                                                (Eq.1)  22 
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where the numerator is the subharmonic component of the mean backscattered signal 
measured over a 2MHz bandwidth centred over the subharmonic frequency (15MHz) 
and the denominator is the mean backscattered signal measured over a 2MHz 
bandwidth over the fundamental frequency (30MHz) of the in vitro case (i.e., 19G 
needle, 3ml·min-1 at RT). 
 
The data analysis used the radio-frequency (RF) data acquired from a pre-selected 
region of interest (ROI) (1.05 mm × 1.6 mm) centred over the focal position of the 
transducer.  The RF data was output and calculations were performed offline using 
MATLAB software (MATLAB 2009A, The MathWorks Inc., Natick, MA, USA). 
Each experiment was repeated three times and 900 independent samples (300 
consecutive frames on 3 lines) in each ROI were collected per experiment. The error 
bars were the standard deviation calculated from three independent measurements. 
For the measurement of attenuation and CTR, a single cycle signal was used as the 
driving pulse. For the measurement of NSI, modified VisualSonics software was used 
to generate a 25-cycle pulse (3% power, PNP equal to -0.67 MPa) and the 
subharmonic response was isolated from the receiving signals. 
 
2.7 Statistics 
A student’s T test was performed between the in vitro case and all other combinations 
of needle gauge size, injection rate and temperature to investigate whether there is a 
significant difference in the mean diameter and acoustic properties of UCAs in the 
frequency range 17-31MHz due to the variation in the needle gauges, injection rate 
and temperature. The significance level was set at 0.05. The results of the student’s T 
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test are marked on the top of each group using the in vitro result as control in Figures 
1 - 5.  
 
2.8 Pressure drop and shear stress in the syringes and needles 
The pressure drop from the syringe to the needle and the shear stress, τ, in the 
syringes and needle were calculated using the equations found in [21]. 
 
3 RESULTS 
 
3.1 Pressure drop and shear stress in the syringes and needles 
Table 3 lists the calculated shear stress in the syringes and needles and the pressure 
drop from the piston in the syringe to the outlet of the needle at different settings. At 
certain injection rates (0.85 ml/min using 1ml-syringe, 3ml/min using 2-ml syringe), 
the pressure drop and the shear stress in the needle increase with increasing needle 
gauge (i.e., decreasing I.D.).  
 
 
 
 
 
 
 
 
 
 
  
 16
Table 3 The calculated velocity and shear stress in the tested syringe (1ml I.D.: 4.78mm, 2ml I.D.: 8.66) and needles (19G, 27G) and the 
pressure drop (Ps - Pn) from syringe to needle (Ps: the pressure in the liquid near the piston in the syringe, Pn: the pressure in the liquid at the 
outlet of the needle) 
 
 
 
 
 
 
 
 
 
 
 
 
Injection 
rate 
(ml/min) 
 
Syringe 
volume  
(ml) 
Syringe 
ID (mm) 
Mean 
velocity in 
syringe 
(mm/s) 
Needle 
Gauges 
Needle ID 
(mm) 
Mean 
velocity in 
needle 
(mm/s) 
Pressure 
drop  
Ps-Pn (Pa) 
Shear stress 
in syringe 
(mPa) 
Shear stress 
in needle 
(Pa) 
0.85 
 
1 4.78 0.79 
19G 0.686 38.35 0.73 1.32 0.45 
27G 0.21 409.22 83.73 1.32 15.59 
3 
 
2 8.66 
 
0.85 
19G 0.686 135.35 9.16 0.78 1.58 
27G 0.21 1444.31 1043.02 0.78 55.02 
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3.2 The variation in diameter, concentration and acoustic characterisation  
In the following figures the headings of the groups are such that ‘Needle Gauge’ 
group indicates that only the needle gauge changed, ‘Injection Rate’ group indicates 
that only the injection rate changed and ‘Temperature’ group indicates that only 
temperature changed with respect to the in vitro data.  For the cases of in vivo data, all 
three parameters changed.  
 
Figure 1 shows the mean diameter of Definity, SonoVue and MicroMarker as a 
function of different injection regimes. The mean diameters in in vitro case are larger 
than the values of Definity and SonoVue shown in Table 1 as the mean diameter in 
this study was from the volume-based size measurement by Mastersizer, while the 
values from the manufacturer use the number-based size measurement. Compared 
with the in vitro case, the mean diameter of Definity decreases with increasing needle 
gauge, decreasing injection rate and increasing temperature. The individual impact of 
needle gauge makes no significant difference in the mean diameter of SonoVue, but 
lower injection rate, and the combined effect of higher temperature and lower 
injection rate show a significant decrease in the mean diameter of SonoVue. 
MicroMarker exhibits the smallest mean diameter of the three UCAs. Unlike the mean 
diameters of Definity and SonoVue, MicroMarker shows no significant variation 
between in vitro and in vivo experimental regimes. 
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Fig.1: Volume-based mean diameter of Definity, SonoVue and MicroMarker under 
different experimental regimes.  Needle gauge group indicating that only the needle 
gauge changed, injection rate group indicating that only the injection rate changed and 
temperature group indicating that only temperature changed with respect to the in 
vitro data.  In vivo data, all three parameters changed as detailed in text. Significance 
determined between ‘in vitro’ data set and other experimental regimes so that no mark 
indicates no significant difference, **P<0.01, ***P<0.001  
 
The concentration of each of the three UCAs significantly decreases with increasing 
needle gauge in Figure 2. Only SonoVue presents a significant increase in 
concentration with decreasing injection rate. Both SonoVue and Definity show a 
decrease in concentration with temperature. In a comparison between in vivo and in 
vitro applications, MicroMarker concentration displays no significant variation but 
both SonoVue and Definity display a reduction in concentration. 
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Fig.2:  Concentration of Definity, SonoVue and MicroMarker under different 
experimental regimes, * P<0.05, **P<0.01, ***P<0.001. Group headings similar to 
that displayed in Figure 1 
 
In Figure 3 the attenuation of ultrasound through the suspensions of Definity, 
SonoVue and MicroMarker in the frequency range 17-31 MHz is presented. No 
significant variation in the attenuation of Definity was found with changing needle 
gauge and injection rate. Compared to the in vitro data SonoVue exhibited significant 
decreases in attenuation with decreasing injection rate, increasing needle gauge and 
temperature. Conversely, for MicroMarker, the attenuation significantly increases 
from RT to BT, but neither increasing needle gauge nor injection rate makes a 
significant difference to attenuation.  
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Fig.3:  The attenuation comparison of Definity, SonoVue and MicroMarker, No mark: 
no significant difference, * P<0.05, **P<0.01, ***P<0.001. Group headings similar to 
that displayed in Figure 1.   
 
From Figure 4, increasing gauge size needle only shows a significant, but small, 
impact on the CTR of SonoVue. Using a lower injection rate decreases the CTR of 
Definity and SonoVue significantly but increases the CTR of MicroMarker. The 
variation in temperature increases the CTR of SonoVue and MicroMarker. Overall a 
change from in vitro to in vivo conditions results in a small but significant decrease in 
CTR for SonoVue and a highly significant increase for MicroMarker.    
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Fig.4:  The CTR comparison of Definity, SonoVue and MicroMarker, no mark: no 
significant difference, ** P<0.01, ***P<0.001. Group headings similar to that 
displayed in Figure 1 
 
The NSI of Definity, SonoVue and MicroMarker are shown in Figure 5. For Definity, 
NSI shows no significant variation with needle gauge and injection rate. Significant 
decrease in NSI of SonoVue was found with increase in temperature. The variation in 
the trend of SonoVue is consistent with the variation of MicroMarker in the 
temperature and in vivo cases.  MicroMarker had the largest NSI of the three agents.  
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Fig.5:  The normalized subharmonic intensity comparison of Definity, SonoVue and 
MicroMarker, No mark: no significant difference, **P<0.01, ***P<0.001. Group 
headings similar to that displayed in Figure 1 
 
4 DISCUSSION 
 
4.1 The impact of needle gauge on the mean diameter, concentration and acoustic 
properties of the MBs at RT 
 
The concentration of Definity, SonoVue and MicroMarker obtained from the study of 
needle gauge size between 19G and 27G at RT agrees with Talu’s study [20] which 
show that increasing needle gauges (i.e., narrower ID) reduces the concentration of 
the MBs because of the aggravated diffusion of the MBs due to an increment in the 
forced compression named as shear stress (Table 3). The concentration of SonoVue 
was found to decrease by far the most in the three UCAs. This may also be the reason 
for the decrease in mean diameter of Definity agreeing with previous studies [20, 21]. 
  
 23
However, no significant difference was found in the mean diameter for SonoVue MB. 
Definity, SonoVue and MicroMarker are poly-disperse MBs of concentration 
1.2×1010MBs/ml [10], 2-5×108 MBs/ml [24] and 2×109 MBs/ ml [26] respectively. 
Talu et al. [20] showed less than 10% variation in mean diameter of in-house MBs 
when using 27G needle at an injection rate of 0.1 ml/sec (3ml/min = 0.05 ml/sec). 
Although the structure and the size distribution of SonoVue MBs are comparable to 
the in-house MBs described in the Barrack et al study, they are different from the 
small MBs (0.95 ± 0.75 µm) with a narrow distribution in Talu et al. [20] study.  
However the concentration of MBs used in this study is similar to Talu’s study 
(0.1/0.5/1×109 MBs/ml) and approximately a factor of 500 greater than that used in the 
Barrack’s study. Therefore it is likely that the differences between the tested agents 
are caused by differences in concentration and size distribution. 
 
For Definity in a frequency range of 17-31MHz and at RT, only the measured NSI 
was found to decrease with increasing gauge needle. However a significant decrease 
was found in the attenuation and CTR of SonoVue at RT with increasing needle 
gauge that may be due to the reduction in mean diameter and concentration of MBs.  
 
4.2 The impact of injection rate on the mean diameter, concentration and acoustic 
properties of the MBs 
 
The reduction in injection rate from 3 ml/min to 0.85 ml/min at RT is found to 
decrease the mean diameter of both SonoVue and Definity MBs. This is not in 
agreement with the trend from previously reported studies [20, 21].  However in our 
study, in addition to the difference in the structure, concentration and size distribution 
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between the tested MBs, from Table 3 it can be seen that at RT the decrease in mean 
diameter from high to low injection rate may be attributed to a lower shear stress 
(0.78 mPa) within the 2ml syringe used for high injection rates compared to a higher 
shear stress (1.32mPa) experienced within the 1ml syringe used for low injections 
rates. The results in Talu’s and Barrack’s studies support these observations as the 
change in mean diameter of MBs in Talu’s study is less than 5% using a 23G needle 
[20]; while in this study using a 19G needle (larger I.D.) a smaller reduction in the 
variation in mean diameter would be expected. The syringe was placed horizontally 
on the syringe pump during injection so it is important to note that at a low injection 
rate there was sufficient time for large MBs to float towards the wall of the syringe 
and therefore be exposed to the increasingly higher shear stress [21, 22, 30]. However, 
the total time of the needle being held horizontally was a maximum of 1 minute from 
set-up to the UCA being output into an Eppendorf. From calculations based upon 
Goertz et al [23], it can be shown that even a bubble of as large a diameter of 5 
micron requires approximately 3 minutes to float from the center of the syringe to the 
syringe wall, which is significantly longer than the limited time of bubble passage 
through the syringe. Unlike Definity, MicroMarker showed no significant variation in 
concentration with changing injection rate. However, the concentration of 
microbubbles decreases for SonoVue with increasing injection rate similar to the 
results in Barrack’s study [21].  
 
For Definity and SonoVue in the frequency range of 17-31 MHz the measured CTR 
was found to decrease significantly with decreasing injection rate with respect to the 
in vitro data.  From Table 3, using 19G needle, the pressure drop and the shear stress 
in the needle at an injection rate of 3 ml/min is 10 times and 5 times greater 
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respectively than the corresponding values at 0.85 ml/min. Additionally, as analysed 
in section 4.2 that the mean diameter of Definity and SonoVue decreased at lower 
injection rate, i.e., large MBs are more likely to be disrupted at a higher injection rate 
than at a lower injection rate.  This may explain the significant reduction in CTR 
observed for SonoVue and Definity at lower injection rates. Conversely a significant 
increase in CTR with injection rate was observed for MicroMarker. The mean 
diameter of MicroMarker was smaller (in vitro case in Figure 1) than that of Definity 
and SonoVue, thus the floatation of large MBs of MicroMarker towards the wall of 
syringe during the slow injection process is likely to have less impact on the size 
distribution and concentration for Definity and SonoVue.  
 
4.3 The impact of temperature on the mean diameter, concentration and acoustic 
properties of the MBs 
 
The mean diameters of SonoVue MBs was shown to increase from RT to BT which 
agreed with previous results [16]. The process of MBs dissolution was previously 
found to be in 3 phases: (1) an initially quick growth, (2) steady dissolution [31], (3) 
phase changes from low vapour pressure to vapour-to-liquid under Laplace pressure 
[32, 33]. In the first growth stage, it was proposed that the increase in temperature 
enabled the expansion of SonoVue MBs by weakening the chemical bonds between 
lipid molecules and changing the shell elasticity and surface tension [16]. However in 
our studies, Definity showed a significant decrease in mean diameter form RT to BT. 
Because of the different shell components of the two UCAs, when close to the phase 
transition temperature, Definity may tend to dissolve faster than SonoVue and lead to 
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the overall reduction in mean diameter. The concentration of both Definity and 
SonoVue decreases significantly at BT.  
 
The results from this study show that the attenuation of SonoVue reduces from RT to 
BT in the frequency range 17-31MHz. Previously published data of SonoVue 
measured at 3.5 MHz and at 100kPa peak negative pressure found attenuation 
increased with temperature below 40oC [19].  However, the frequency of insonation in 
this study is much greater than the reported resonance frequency range of SonoVue 
MBs (1-3 MHz) [25] and we have shown that the concentration of SonoVue MBs 
reduces significantly at BT. In comparison, in our study the attenuation of 
MicroMarker was found to increase significantly with temperature suggesting that at 
higher temperatures there may be an increase in mean diameter of the MB population 
giving a larger attenuation. Previous studies at RT have shown that MicroMarker 
demonstrated an increase in attenuation up to 21MHz [34]. In addition the higher 
values of attenuation exhibited by MicroMarker in BT measurements compared to RT 
measurements in our studies are consistent with similar measurements made by 
Raymond et al [14] at lower frequencies. The variation of acoustical properties for 
Definity as a function of temperature is not included in this paper.   
 
The CTRs of SonoVue and MicroMarker were found to significantly increase at BT 
compared with RT. For SonoVue, although the number of microbubbles decreased at 
BT, there was an increase in mean diameter. The increased CTR may be caused by the 
larger scattering cross-section that can be attributed to an increase in mean diameter. 
The NSIs of SonoVue and MicroMarker decrease from RT to BT. de Jong et al (2000) 
has shown that maximal subharmonics are generated by microbubbles resonating at 
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half of the driving frequency [35], which is fixed at 15MHz in this study. As we have 
shown in Figure 1 that the diameters of SonoVue and MicroMarker bubbles increase 
with temperature they will therefore resonate at lower frequencies potentially outwith 
the frequency bandwidth of the transducer used in this study.  
 
4.4 The combined effect of needle gauge, injection rate and temperature and future 
research 
 
Based on the above discussions of the individual impact of the three factors (needle 
gauge, injection rate and temperature), no clear trend is evident in the changes in the 
mean diameter, concentration and acoustic parameters of the three UCAs. However, 
for SonoVue and MicroMarker, significant variation was found in both size and 
acoustic properties when needle gauge, temperature and injection rate were changed 
from a typical in vitro to a typical in vivo experimental design. The differences 
between the in vivo and in vitro settings are the cumulative result of variations in the 
parameters with one or more factors predominating and effectively determining the 
measured outcome. In the future, studying the variation in single MB of different 
diameters at distinct environments might be of interest to give a quantitative answer to 
this question. Details of this variation will allow researchers to estimate the response 
of MBs under different environments and explain the discrepancy between in vitro 
and in vivo experiments. 
 
5 CONCLUSION 
In this paper, the influence of needle gauge and injection rate on the mean diameter, 
concentration and acoustic properties of Definity, SonoVue and MicroMarker over the 
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frequency range of 17-31MHz and the influence of temperature on SonoVue and 
MicroMarker over the same frequency range were investigated. In particular, the 
influence of these parameters on typical in vitro settings (19G needle, 3ml/min at RT) 
and in vivo settings (27G needle, 0.85ml/min at BT) were compared. Although no 
consistent trend was found for each individual experimental set-up change, we found 
that the mean volume-based diameter and concentration of both SonoVue and 
Definity reduced significantly with a tenfold reduction in concentration when 
measured under typical in vivo experimental conditions compared to in vitro 
conditions. For MicroMarker, neither the mean volume-based diameter nor 
concentration changed significantly. With respect to the acoustic properties of the 
UCAs we found that the attenuation, CTR and NSI of SonoVue significantly 
decreased when moving from typical in vitro to in vivo experimental set-ups. From 
our limited measurements of Definity, we found no significant change in attenuation, 
CTR and NSI with needle gauge.  For MicroMarker we found that, while the 
attenuation and CTR increased, the NSI decreased when changing from typical in 
vitro to in vivo experimental set-ups. These results suggest that in similarity to results 
obtained at lower frequencies, care must be taken in translating results obtained in 
vitro to preclinical in vivo imaging studies. Moreover based on these results, it is 
likely that other variables such as choice of diluent (saline or blood) and the gas 
saturation level of the testing environment may have significant effect on the acoustic 
measurements and thus are worthy of further exploration at high frequencies.  
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Research highlights  
 
 When changing from typical in vitro to in vivo experimental conditions, Definity 
and SonoVue demonstrated a significant reduction in mean diameter. 
MicroMarker did not demonstrate any significant change in diameter.  
 When changing from typical in vitro to in vivo experimental conditions, Definity 
and SonoVue demonstrated a significant tenfold reduction in concentration.  
Micromarker did not demonstrate any significant change in concentration.  
 When changing from typical in vitro to in vivo experimental conditions, SonoVue 
demonstrated a significant reduction in attenuation, contrast to tissue ratio (CTR) 
and normalized subharmonic intensity (NSI).  
 When changing from typical in vitro to in vivo experimental conditions, 
MicroMarker demonstrated a significant increase in attenuation, CTR but a 
reduction in NSI.   
 Care must be taken in translating results obtained in vitro to preclinical imaging 
studies.   
 
 
 
 
